These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 15634796)

  • 1. Assay for ubiquitin ligase activity: high-throughput screen for inhibitors of HDM2.
    Davydov IV; Woods D; Safiran YJ; Oberoi P; Fearnhead HO; Fang S; Jensen JP; Weissman AM; Kenten JH; Vousden KH
    J Biomol Screen; 2004 Dec; 9(8):695-703. PubMed ID: 15634796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells.
    Yang Y; Ludwig RL; Jensen JP; Pierre SA; Medaglia MV; Davydov IV; Safiran YJ; Oberoi P; Kenten JH; Phillips AC; Weissman AM; Vousden KH
    Cancer Cell; 2005 Jun; 7(6):547-59. PubMed ID: 15950904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors.
    Lai Z; Yang T; Kim YB; Sielecki TM; Diamond MA; Strack P; Rolfe M; Caligiuri M; Benfield PA; Auger KR; Copeland RA
    Proc Natl Acad Sci U S A; 2002 Nov; 99(23):14734-9. PubMed ID: 12407176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase.
    Honda R; Yasuda H
    Oncogene; 2000 Mar; 19(11):1473-6. PubMed ID: 10723139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ubiquitin-protein ligase activity of Hdm2 is inhibited by nucleic acids.
    Linares LK; Scheffner M
    FEBS Lett; 2003 Nov; 554(1-2):73-6. PubMed ID: 14596917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative assays of Mdm2 ubiquitin ligase activity and other ubiquitin-utilizing enzymes for inhibitor discovery.
    Auger KR; Copeland RA; Lai Z
    Methods Enzymol; 2005; 399():701-17. PubMed ID: 16338390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyubiquitination of p53 by a ubiquitin ligase activity of p300.
    Grossman SR; Deato ME; Brignone C; Chan HM; Kung AL; Tagami H; Nakatani Y; Livingston DM
    Science; 2003 Apr; 300(5617):342-4. PubMed ID: 12690203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of approaches for screening for ubiquitin ligase inhibitors.
    Sun Y
    Methods Enzymol; 2005; 399():654-63. PubMed ID: 16338387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The contribution of the acidic domain of MDM2 to p53 and MDM2 stability.
    Argentini M; Barboule N; Wasylyk B
    Oncogene; 2001 Mar; 20(11):1267-75. PubMed ID: 11313871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-throughput screening for inhibitors of the e3 ubiquitin ligase APC.
    Huang J; Sheung J; Dong G; Coquilla C; Daniel-Issakani S; Payan DG
    Methods Enzymol; 2005; 399():740-54. PubMed ID: 16338393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Missing the target: ubiquitin ligase drugs stall.
    Garber K
    J Natl Cancer Inst; 2005 Feb; 97(3):166-7. PubMed ID: 15687356
    [No Abstract]   [Full Text] [Related]  

  • 12. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53.
    Honda R; Yasuda H
    EMBO J; 1999 Jan; 18(1):22-7. PubMed ID: 9878046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR.
    Parks DJ; Lafrance LV; Calvo RR; Milkiewicz KL; Gupta V; Lattanze J; Ramachandren K; Carver TE; Petrella EC; Cummings MD; Maguire D; Grasberger BL; Lu T
    Bioorg Med Chem Lett; 2005 Feb; 15(3):765-70. PubMed ID: 15664854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells.
    Grasberger BL; Lu T; Schubert C; Parks DJ; Carver TE; Koblish HK; Cummings MD; LaFrance LV; Milkiewicz KL; Calvo RR; Maguire D; Lattanze J; Franks CF; Zhao S; Ramachandren K; Bylebyl GR; Zhang M; Manthey CL; Petrella EC; Pantoliano MW; Deckman IC; Spurlino JC; Maroney AC; Tomczuk BE; Molloy CJ; Bone RF
    J Med Chem; 2005 Feb; 48(4):909-12. PubMed ID: 15715460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Themes and variations on ubiquitylation.
    Weissman AM
    Nat Rev Mol Cell Biol; 2001 Mar; 2(3):169-78. PubMed ID: 11265246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mdm2-SUMO1: is bigger better?
    Melchior F; Hengst L
    Nat Cell Biol; 2000 Sep; 2(9):E161-3. PubMed ID: 10980713
    [No Abstract]   [Full Text] [Related]  

  • 17. Development of a ubiquitin transfer assay for high throughput screening by fluorescence resonance energy transfer.
    Boisclair MD; McClure C; Josiah S; Glass S; Bottomley S; Kamerkar S; Hemmilä I
    J Biomol Screen; 2000 Oct; 5(5):319-28. PubMed ID: 11080690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-Throughput Screening of HECT E3 Ubiquitin Ligases Using UbFluor.
    Foote PK; Krist DT; Statsyuk AV
    Curr Protoc Chem Biol; 2017 Sep; 9(3):174-195. PubMed ID: 28910856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53.
    Boyd SD; Tsai KY; Jacks T
    Nat Cell Biol; 2000 Sep; 2(9):563-8. PubMed ID: 10980695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An essential function of the extreme C-terminus of MDM2 can be provided by MDMX.
    Uldrijan S; Pannekoek WJ; Vousden KH
    EMBO J; 2007 Jan; 26(1):102-12. PubMed ID: 17159902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.